Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $38000.0.

  • Niagen Bioscience's Amortizatization of Intangibles changed 0.0% to $38000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $151000.0, marking a year-over-year increase of 16064.26%. This contributed to the annual value of $151000.0 for FY2024, which is 443.04% down from last year.
  • As of Q3 2025, Niagen Bioscience's Amortizatization of Intangibles stood at $38000.0, which was down 0.0% from $38000.0 recorded in Q2 2025.
  • Niagen Bioscience's 5-year Amortizatization of Intangibles high stood at $299000.0 for Q1 2022, and its period low was -$362000.0 during Q4 2023.
  • In the last 5 years, Niagen Bioscience's Amortizatization of Intangibles had a median value of $126000.0 in 2021 and averaged $92736.8.
  • As far as peak fluctuations go, Niagen Bioscience's Amortizatization of Intangibles surged by 13730.16% in 2022, and later crashed by 28952.88% in 2023.
  • Niagen Bioscience's Amortizatization of Intangibles (Quarter) stood at $126000.0 in 2021, then surged by 51.59% to $191000.0 in 2022, then tumbled by 289.53% to -$362000.0 in 2023, then surged by 110.5% to $38000.0 in 2024, then changed by 0.0% to $38000.0 in 2025.
  • Its last three reported values are $38000.0 in Q3 2025, $38000.0 for Q2 2025, and $37000.0 during Q1 2025.